Answers are grounded in this paper and cite their sources.
This analysis reveals links between plasma biomarkers and increased mortality risks, suggesting clinical considerations for their use.
Plasma biomarkers of neurodegeneration, particularly GFAP and NfL, were associated with increased risk of all-cause, dementia-specific, and cardiovascular-specific mortality in a biracial cohort. These associations should be considered when assessing links between these biomarkers and other outcomes, as well as when used in clinical practice.
No takes yet. Share an insight, caveat, or question.
Sawyer et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: